logo
Breadcrumbs Image

Radiopharmaceuticals in Nuclear Medicine Market

Radiopharmaceuticals in Nuclear Medicine Market

Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2021 Professional Edition


Date: Apr-2021 | Id: MACRC-36659 | Geographical Scope: Global | Publisher: HNY Research

The research team projects that the Radiopharmaceuticals in Nuclear Medicine market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)

By Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes

By Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other

By Regions/Countries:
North America
United States
Canada
Mexico

East Asia
China
Japan
South Korea

Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland

South Asia
India
Pakistan
Bangladesh

Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar

Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman

Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo

Oceania
Australia
New Zealand

South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador

Rest of the World
Kazakhstan

Points Covered in The Report
The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.
The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.
Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.
The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global  market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Radiopharmaceuticals in Nuclear Medicine 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.
Market Analysis by Product Type: The report covers majority Product Types in the Radiopharmaceuticals in Nuclear Medicine Industry, including its product specifcations by each key player, volume, sales by Volume and Value (M USD).
Markat Analysis by Application Type: Based on the Radiopharmaceuticals in Nuclear Medicine Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Radiopharmaceuticals in Nuclear Medicine market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Get Started with Request an Overview
Get Started with Download Brochure
Get Started with Request Methodology
Get Started with Share Customization
Get Started with Submit RFP
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Radiopharmaceuticals in Nuclear Medicine Revenue
1.4 Market Analysis by Type
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Diagnostic Radiopharmaceuticals
1.4.3 Therapy Radiopharmaceuticals
1.4.4 Enriched Stable Isotopes
1.5 Market by Application
1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application: 2022-2027
1.5.2 Diagnostic Application
1.5.3 Therapeutic Application
1.5.4 Research
1.5.5 Pharmaceutical
1.5.6 Other
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Radiopharmaceuticals in Nuclear Medicine Market
1.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Radiopharmaceuticals in Nuclear Medicine Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Radiopharmaceuticals in Nuclear Medicine Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Market Share by Region (2016-2021)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Revenue Market Share by Region (2016-2021)
3.3 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume
3.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.3.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume
3.4.1 East Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.6.1 South Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.7.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.8.1 Middle East Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.9.1 Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.10.1 Oceania Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.11.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.11.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.12.1 Rest of the World Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Market Share by Type (2016-2021)
14.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Revenue Market Share by Type (2016-2021)
14.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Application (2016-2021)
15.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business
16.1 Bracco Imaging S.P.A.
16.1.1 Bracco Imaging S.P.A. Company Profile
16.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Cambridge Isotope Laboratories, Inc.
16.2.1 Cambridge Isotope Laboratories, Inc. Company Profile
16.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Cardinal Health, Inc.
16.3.1 Cardinal Health, Inc. Company Profile
16.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Covidien, Plc
16.4.1 Covidien, Plc Company Profile
16.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Specification
16.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Eczacibasi-Monrol
16.5.1 Eczacibasi-Monrol Company Profile
16.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Specification
16.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Fujifilm Holdings Corporation
16.6.1 Fujifilm Holdings Corporation Company Profile
16.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
16.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 GE Healthcare (Subsidiary Of General Electric Company)
16.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Profile
16.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 IBA Group
16.8.1 IBA Group Company Profile
16.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Specification
16.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Isotec, Inc. (Sigma-Aldrich)
16.9.1 Isotec, Inc. (Sigma-Aldrich) Company Profile
16.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Lantheus Medical Imaging, Inc.
16.10.1 Lantheus Medical Imaging, Inc. Company Profile
16.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Nordion, Inc.
16.11.1 Nordion, Inc. Company Profile
16.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Ntp Radioisotopes (Pty), Ltd.
16.12.1 Ntp Radioisotopes (Pty), Ltd. Company Profile
16.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Siemens Healthcare (Subsidiary Of Siemens AG)
16.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Profile
16.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Taiyo Nippon Sanso Corporation
16.14.1 Taiyo Nippon Sanso Corporation Company Profile
16.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
16.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Urenco Limited
16.15.1 Urenco Limited Company Profile
16.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Specification
16.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Rotem Industries, Ltd., Inc.
16.16.1 Rotem Industries, Ltd., Inc. Company Profile
16.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Australian Nuclear Association And Technology Organization (ANSTO)
16.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Profile
16.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.18 Board of Radiation And Isotope Technology (BRIT)
16.18.1 Board of Radiation And Isotope Technology (BRIT) Company Profile
16.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.19 Institute of Atomic Energy Polatom Radioisotope Centre
16.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Profile
16.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Specification
16.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.20 Institute of Isotopes Co., Ltd.
16.20.1 Institute of Isotopes Co., Ltd. Company Profile
16.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.21 Institute Of Radioelement (IRE)
16.21.1 Institute Of Radioelement (IRE) Company Profile
16.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Radiopharmaceuticals in Nuclear Medicine Manufacturing Cost Analysis
17.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Radiopharmaceuticals in Nuclear Medicine
17.4 Radiopharmaceuticals in Nuclear Medicine Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Radiopharmaceuticals in Nuclear Medicine Distributors List
18.3 Radiopharmaceuticals in Nuclear Medicine Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Radiopharmaceuticals in Nuclear Medicine (2022-2027)
20.2 Global Forecasted Revenue of Radiopharmaceuticals in Nuclear Medicine (2022-2027)
20.3 Global Forecasted Price of Radiopharmaceuticals in Nuclear Medicine (2016-2027)
20.4 Global Forecasted Production of Radiopharmaceuticals in Nuclear Medicine by Region (2022-2027)
20.4.1 North America Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.3 Europe Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.7 Africa Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.9 South America Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.2 East Asia Market Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.3 Europe Market Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Countriy
21.4 South Asia Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.5 Southeast Asia Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.6 Middle East Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.7 Africa Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.8 Oceania Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.9 South America Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.10 Rest of the world Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer

Add to Cart

Single User

$ 2890.00

Site License

$ 4335.00

Enterprisewide

$ 5780.00